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Abstract
Genome-wide association studies with metabolic traits (mGWAS) uncovered many genetic
variants that influence human metabolism. These genetically influenced metabotypes
(GIMs) contribute to our metabolic individuality, our capacity to respond to environmental
challenges, and our susceptibility to specific diseases. While metabolic homeostasis in
blood is a well investigated topic in large mGWAS with over 150 known loci, metabolic
detoxification through urinary excretion has only been addressed by few small mGWAS
with only 11 associated loci so far. Here we report the largest mGWAS to date, combining
targeted and non-targeted 1H NMR analysis of urine samples from 3,861 participants of the
SHIP-0 cohort and 1,691 subjects of the KORA F4 cohort. We identified and replicated 22
loci with significant associations with urinary traits, 15 of which are new (HIBCH, CPS1,
AGXT, XYLB, TKT, ETNPPL, SLC6A19, DMGDH, SLC36A2, GLDC, SLC6A13, ACSM3,
SLC5A11, PNMT, SLC13A3). Two-thirds of the urinary loci also have a metabolite associa-
tion in blood. For all but one of the 6 loci where significant associations target the same
metabolite in blood and urine, the genetic effects have the same direction in both fluids. In
contrast, for the SLC5A11 locus, we found increased levels ofmyo-inositol in urine whereas
mGWAS in blood reported decreased levels for the same genetic variant. This might
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indicate less effective re-absorption ofmyo-inositol in the kidneys of carriers. In summary,
our study more than doubles the number of known loci that influence urinary phenotypes. It
thus allows novel insights into the relationship between blood homeostasis and its regula-
tion through excretion. The newly discovered loci also include variants previously linked to
chronic kidney disease (CPS1, SLC6A13), pulmonary hypertension (CPS1), and ischemic
stroke (XYLB). By establishing connections from gene to disease via metabolic traits our
results provide novel hypotheses about molecular mechanisms involved in the etiology of
diseases.
Author Summary
Human metabolism is influenced by genetic and environmental factors defining a person’s
metabolic individuality. This individuality is linked to personal differences in the ability to
react on metabolic challenges and in the susceptibility to specific diseases. By investigating
how common variants in genetic regions (loci) affect individual blood metabolite levels,
the substantial contribution of genetic inheritance to metabolic individuality has been
demonstrated previously. Meanwhile, more than 150 loci influencing metabolic homeosta-
sis in blood are known. Here we shift the focus to genetic variants that modulate urinary
metabolite excretion, for which only 11 loci were reported so far. In the largest genetic
study on urinary metabolites to date, we identified 15 additional loci. Most of the 26 loci
also affect blood metabolite levels. This shows that the metabolic individuality seen in
blood is also reflected in urine, which is expected when urine is regarded as “diluted
blood”. Nonetheless, we also found loci that appear to primarily influence metabolite
excretion. For instance, we identified genetic variants near a gene of a transporter that
change the capability for renal re-absorption of the transporter’s substrate. Thus, our find-
ings could help to elucidate molecular mechanisms influencing kidney function and the
body’s detoxification capabilities.
Introduction
Genome-wide association studies with metabolic traits (mGWAS) investigate the relationship
between genetic variance and metabolic phenotypes (metabotypes). In 2008, Gieger et al. pre-
sented the first mGWAS in serum of 284 individuals [1]. Since then, numerous mGWAS using
different analytical platforms and ever larger study populations were published [2–8]. These
studies discovered more than 150 genetic loci that associate with blood levels of more than 300
distinct metabolites. We refer to these loci as the genetically influenced metabotypes (GIMs),
their ensemble defining the genetic part of human metabolic individuality. Many of the single
nucleotide polymorphisms (SNPs) that associate with metabolic traits map to genetic regions
coding for enzymes or metabolite transporters that are biochemically linked to the associated
metabolites. Moreover, a large number of these GIMs have been previously linked to clinically
relevant phenotypic traits. As intermediate traits on the pathways of many disorders, these
GIMs have become valuable tools that allow unraveling disease mechanisms on the molecular
level [9].
However, so far mGWAS have mostly been limited to studies of serum or plasma metabolite
levels, thereby focusing on genetically influenced metabolic homeostasis in blood. Only a few
studies investigated urine as a complementary body fluid enabling studies of kidney function
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and the detoxification capabilities of the human body. In 2011, we published the first mGWAS
in urine [10] using proton nuclear magnetic resonance spectroscopy (1H NMR) to determine
metabolite concentrations in urine of 862 male participants of the SHIP-0 cohort. We identi-
fied five genetic loci (SLC6A20, AGXT2, NAT2, HPD, and SLC7A9) that modulate urinary
metabolite levels. While for this study metabolite concentrations were manually derived from
the NMR spectra for a targeted set of metabolites, Nicholson et al. [5] directly used spectral fea-
tures as abstract, non-targeted urinary metabolic traits in an mGWAS. Based on data for 211
participants of the MolTWIN and MolOBB studies, the authors identified SNPs at three loci
(ALMS1/NAT8, AGXT2, and PYROXD2) that were associated with metabolic traits in urine.
Two of these loci (ALMS1/NAT8 and PYROXD2) were replicated in an NMR-based mGWAS
published by Montoliu et al. For that study, the authors analyzed non-targeted urinary traits
from 265 subjects from the São Paolo metropolitan area [11]. Recently, Rueedi et al. [12]
reported significant associations of NMR-derived non-targeted urinary traits in ten loci
(ALMS1/NAT8, ACADL, AGXT2, NAT2, ABO, PYROXD2, ACADS, PSMD9, SLC7A9, and
FUT2) using data from 835 participants of the CoLaus study, thus bringing the total number of
reported urinary GIMs to eleven.
Here, we substantially extend our previous mGWAS with metabolic traits in urine, both in
size and in scope. First, we metabolically characterize the urine samples of 3,861 male and
female participants of the SHIP-0 study, thereby quadrupling the sample size when compared
to previous studies. Second, we combine both targeted and non-targeted NMR-based metabo-
lomics. In this way, we implement the approaches used in the studies by Nicholson et al., Mon-
toliu et al., and Rueedi et al. alongside the targeted metabolomics approach used in our
previous study. For an unbiased interpretation of our mGWAS results, we apply tools for evi-
dence-based locus-to-gene mapping and automated assignment of metabolites to non-targeted
NMR spectral features. Finally, besides determining the overlap of variants identified in our
study with variants previously linked to clinical traits, we specifically investigate the overlap
between variants influencing metabolic traits in both urine and blood.
Results
Our study is based on one-dimensional 1H NMR spectra of urine samples from 3,861 geno-
typed participants in the SHIP-0 cohort (see Methods). For the targeted metabolomics analysis,
we manually quantified a set of 60 metabolites in these spectra (Fig 1A). For the non-targeted
analysis, we used the same spectra and applied an automated processing algorithm to align the
spectra and to perform dimensionality reduction [13]. In the subsequent analysis, we screened
the targeted and the non-targeted metabolic traits as well as the pairwise ratios within each
trait type for associations with genotyped and imputed variants in a two-step approach (Fig
1B). We identified a total of 23 genetic loci that display significant associations with targeted
and/or non-targeted metabolic traits (Fig 2, Tables 1 and 2). All but one of the discovered loci
replicated in data from the KORA F4 cohort (N = 1,691). For 15 loci, our study is, to the best of
our knowledge, the first to report associations with urinary traits. For 7 of these 15 loci, associa-
tions have previously been reported with blood metabolites. Thus, 8 loci are entirely new (Fig
3). Finally, 11 of the 22 replicated loci host significantly associated variants that were previously
associated with phenotypes of clinical relevance (Table 3).
mGWAS with targeted and non-targeted NMR features
For the targeted metabolomics analysis, the 1H NMR spectra were manually annotated to
derive absolute metabolite concentrations (out of a panel of 60 compounds) for each sample.
For the non-targeted analysis, the same spectra were automatically aligned and processed using
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Fig 1. Study design. (a) Genotyping and metabotyping of 3,861 SHIP-0 study participants. One-dimensional 1H NMR spectra of the urine samples were
recorded to derive targeted and non-targeted metabolic traits. (b) Two-staged mGWAS. First stage: genome-wide association tests using genotyped SNPs
and 15,379 targeted and non-targeted traits. Second stage: fine mapping of regions with potentially significant associations using imputed SNPs. (c)
Replication and interpretation. Genome-wide significantly associated SNPs were assigned to one of 23 distinct genetic loci. The loci and the significantly
associated non-targeted traits were annotated using algorithmic approaches. 22 of the 23 loci could be replicated using genotype and metabotype data from
1,691 KORA F4 participants.
doi:10.1371/journal.pgen.1005487.g001
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 4 / 28
the FOCUS package [13]. This resulted in NMR signal intensities at 166 distinct spectral posi-
tions (“chemical shifts”) per sample (see Methods). In previous mGWAS, we demonstrated the
potential of testing pairwise ratios of metabolite concentrations to boost genetic association sig-
nals [1, 4, 6, 8, 10, 21, 53]. Recently, we showed that this approach can also be successfully
applied to NMR-based mGWAS with non-targeted features [22]. Thus, we calculated the pair-
wise ratios of all metabolite concentrations with at least 300 valid data points over all samples
(55×54/2 = 1,485 ratios of targeted traits) and NMR signal intensities (166×165/2 = 13,695
ratios of non-targeted traits), respectively (Fig 1A). Out of all 15,401 metabolic features (tar-
geted and non-targeted traits and the ratios thereof), a total of 15,379 features with at least 300
valid data points were screened for genetic associations using 620,456 genotyped autosomal
SNPs (Fig 1B). To this end, we computed age- and sex-adjusted linear models under the
assumption of additive genetic effects for each SNP-metabolic trait pair. A total of 499 geno-
typed variants display associations with metabolic traits with P-values below 5×10−8.
Fine-mapping of chromosomal regions with associated variants
We used the 499 variants identified in the mGWAS to tag 54 distinct chromosomal regions at
a window size of at least 2 Mb (centered to the tag SNPs). We then performed additional asso-
ciation studies using imputed variants (1000 genomes project imputation) in the tagged regions
(Fig 1B). We considered associations with a P-value below the Bonferroni-adjusted significance
Fig 2. Manhattan plot of genetic associations to targeted and non-targeted traits. SNPs are plotted according to chromosomal location and the-log10
transformed P-value of the strongest association with targeted traits (top) and non-targeted traits (bottom). In case of associations with ratios, only
associations with P-gain exceeding 15,180 (targeted metabolic traits) or 138,610 (non-targeted traits) were considered. Associations of genome-wide
significance (P < 3.25×10−12) are plotted in red. Triangles indicate associations with P < 1.0×10−100. Significant associations within a physical distance of 1
Mb were assigned to a locus labeled after the most likely causative gene (as determined using an evidence-based approach for the identification of candidate
genes; see Methods).
doi:10.1371/journal.pgen.1005487.g002
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threshold of α’ = 5×10−8/15,379 = 3.25×10−12 to be genome-wide significant. For ratio traits,
we also required the P-gain to be greater than 1.52×104 for targeted traits and 1.38×105 for
non-targeted traits (10 times the number of tested traits [53]). P-gain reflects the increase of
association strength with the ratio trait when compared to the P-values that result from associ-
ations with the individual traits buildinging the ratio. A total of 2,882 genotyped or imputed
SNPs display association signals below P< 3.25×10−12 and, in case of ratios, above the imposed
P-gain threshold (Fig 2). All significantly associated SNPs within a physical distance of 1 Mb
were assigned to one of 23 distinct genetic loci. Three loci display significant association signals
only when imputed SNPs were used, and 8 loci show significant associations only when pair-
wise ratios of metabolic traits were considered. Twelve loci show significant associations in
both targeted and non-targeted data sets. Three loci are only significantly associated with tar-
geted traits (i.e., quantified metabolite concentrations or ratios thereof), whereas 8 loci are only
significantly associated with non-targeted traits (spectral features or ratios thereof) (Fig 3). For
each locus, we list the SNP that displays the strongest association signal (lead SNP) and its
associated metabolic trait in Tables 1 and 2. In addition, we provide boxplots, regional
Table 1. Fifteen genetic loci as discovered in the SHIP-0 data set and their most significant associations to targetedmetabolic traits.
Genetic data Associated metabolic trait
Locus Lead SNP Chr Position EA EAF Trait or pairwise
ratio
N beta’ P P-gain Replicated Non-
targeted
CPS1 rs715 2 211,543,055 C 0.31 glycine/threonine 3,472 0.1409 8.46×10−31 9.89×1010 ● ●
XYLB rs3132440 3 38,395,562 C 0.35 glycolate 3,596 0.0752 2.95×10−14 ● –
SLC6A20 rs17279437 3 45,814,094 A 0.11 N,N-dimethylglycine/
alanine
3,671 -0.2827 8.43×10−60 1.36×1013 ● ●
ETNPPL rs56043887 4 109,705,967 T 0.49 ethanolamine 3,433 -0.0613 7.14×10−28 ● ●
SLC6A19 rs11133665 5 1,188,285 A 0.26 histidine/τ-
methylhistidine
2,826 -0.1569 2.40×10−26 7.52×108 ● ●
AGXT2 rs37369 5 35,037,115 T 0.09 3-aminoisobutyrate 3,311 2.2240 2.37×10−252 ● ●
DMGDH rs6453429 5 78,371,861 T 0.18 N,N-dimethylglycine/
betaine
3,611 0.1918 1.52×10−28 1.83×1015 ● ●
SLC36A2 rs3846710 5 150,698,806 C 0.17 glycine/citrate 3,816 -0.1225 2.09×10−15 5.26×104 ● ●
NAT2 rs1495743 8 18,273,300 G 0.23 formate/acetate 3,720 0.2688 1.63×10−67 2.86×107 ● ●
GLDC rs1755615 9 6,643,754 C 0.21 glycine/alanine 3,678 0.0999 1.34×10−12 2.83×105 ● –
SLC6A13 rs11062102 12 348,785 T 0.36 3-aminoisobutyrate 3,211 -0.1755 1.06×10−17 ● ●
HPD rs4760099 12 122,318,723 A 0.15 2-hydroxyisobutyrate 3,835 -0.1636 2.20×10−80 ● ●
PNMT rs7219014 17 37,624,790 A 0.25 histidine/τ-
methylhistidine
2,841 -0.1560 4.26×10−26 4.27×104 ● ●
SLC7A9 rs7247977 19 33,358,355 C 0.35 lysine 888 0.3518 9.61×10−26 ● –
SLC13A3 rs941206 20 45,261,041 C 0.13 succinate/citrate 3,785 0.1245 1.43×10−16 1.78×108 ● ●
Chr/Position: Chromosomal location of the SNP according to the human reference genome (GRCh37). EA/EAF: Effect allele and frequency. Trait or
pairwise ratio: Tested metabolic trait. In case of ratios, the trait that shows the stronger association signal is in the numerator. N: Number of samples for
which both genotype and phenotype data were available for the tested SNP/metabolic trait pair. beta’: beta’ is deﬁned as 10beta-1 where beta depicts the
relative effect size representing the slope of the regression line in the linear model when using log10-scaled metabolic traits and the occurrence of the
SNP’s minor allele (coded as 0,1, and 2). Thus, beta’ describes the relative difference per minor allele copy for non-scaled metabolic traits in comparison
to the estimated mean of the metabolic trait in the major homozygote test subjects. P-gain: Deﬁned as min(P(M1)/P(M1/M2), P(M2)/P(M1/M2)), where M1
and M2 represent the two traits of which the ratio M1/M2 is built. Replicated: SNP/metabolic trait pair was replicated in KORA F4 (P < 1.32×10
−3) (S1
Table). Non-targeted: SNP or proxy in linkage disequilibrium (LD) is also associated with a non-targeted metabolic trait (P < 3.25×10−12) (Table 2).
doi:10.1371/journal.pgen.1005487.t001
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 6 / 28
association plots, and Q-Q plots for each locus in S2 Fig. The summary statistics for all associa-
tion signals with P< 0.05 (P< 1×10−4 and P-gain 10 for associations with ratios) for each
tested SNP can be downloaded from http://www.gwas.eu.
Systematic assignment of loci to genes and annotation of non-targeted
metabolic traits
In general, the biological interpretation of association results from mGWAS requires the map-
ping of SNPs to candidate genes that are most likely causally linked to the observed changes in
Table 2. Twenty genetic loci as discovered in the SHIP-0 data set and their most significant associations to non-targetedmetabolic traits.
Genetic data Associated metabolic trait
Locus Lead SNP Chr Position EA EAF Trait or pairwise
ratio
N beta’ P P-gain Metabomatching Replicated Targeted
NAT8 rs10178409 2 73,855,507 T 0.22 2.031 ppm 3,811 0.1988 1.04×10−95 – N-acetylaspartate a ● –
HIBCH rs13006833 2 191,205,499 G 0.39 1.067 ppm/
1.049 ppm
3,552 0.0293 2.06×10−20 4.60×1018 – ● –
CPS1 rs715 2 211,543,055 C 0.31 3.555 ppm/
2.547 ppm
3,536 0.1760 2.80×10−25 3.49×109 glycine b ● ●
AGXT rs6748734 2 241,837,452 A 0.29 1.086 ppm 3,800 0.0861 6.94×10−18 – α-ketoisovalerate a ● –
SLC6A20 rs17279437 3 45,814,094 A 0.11 2.916 ppm 3,841 -0.2039 7.88×10−22 – N,N-dimethylglycine ● ●
TKT rs4687717 3 35,282,188 T 0.43 4.094 ppm/
7.664 ppm
3.632 0.0476 4.49×10−13 6.97×106 gluconate a ● –
ETNPPL rs7437890 4 109,711,658 C 0.50 3.126 ppm 3,830 -0.0647 2.03×10−16 – ethanolamine – ●
SLC6A19 rs11750211 5 1,183,560 T 0.24 6.877 ppm 3,563 -0.1100 1.92×10−16 – tyrosine b – ●
AGXT2 rs37369 5 35,037,115 T 0.09 1.171 ppm/
1.973 ppm
3,828 1.2772 7.48×10−262 4.99×109 3-aminoisobutyrate ● ●
DMGDH rs6453427 5 78,361,789 A 0.20 2.916 ppm/
5.236 ppm
3,754 0.1566 4.82×10−13 4.66×105 N,N-dimethylglycine a – ●
SLC36A2 rs3846710 5 150,698,806 C 0.17 3.555 ppm/
2.650 ppm
3,843 -0.1355 5.65×10−15 1.11×106 glycine ● ●
NAT2 rs35246381 8 18,272,535 C 0.23 2.159 ppm/
3.324 ppm
3,841 1.1291 2.70×10−202 6.98×10110 butyrate a,b ● ●
ABO rs550057 9 136,146,597 T 0.29 2.031 ppm/
2.049 ppm
3,805 -0.0869 5.85×10−30 1.64×109 N-acetylaspartate a – –
PYROXD2 rs11598867 10 100,146,084 A 0.30 2.854 ppm 3,079 -0.3727 < 1.00×10−307 – trimethylamine a ● –
SLC6A13 rs11062102 12 348,785 T 0.36 1.190 ppm 3,724 -0.1568 4.59×10−16 – 3-aminoisobutyrate a ● ●
HPD rs1916333 12 122,458,637 C 0.15 1.345 ppm/
7.664 ppm
3,798 -0.1691 6.95×10−78 1.64×1017 2-hydroxyisobutyrate b ● ●
ACSM3 rs11645002 16 20,617,841 A 0.08 1.257 ppm/
1.067 ppm
3,800 0.1312 2.59×10−17 9.48×108 3-hydroxyisovalerate ● –
SLC5A11 rs17702912 16 25,002,600 T 0.07 3.594 ppm/
1.067 ppm
3,860 0.5171 9.24×10−66 6.02×1019 myo-inositol a ● –
PNMT rs8069451 17 37,504,933 C 0.24 6.877 ppm 3,842 -0.1093 1.88×10−17 – tyrosine b – ●
SLC13A3 rs941206 20 45,261,041 C 0.13 2.395 ppm/
2.650 ppm
3,828 0.1185 6.30×10−14 2.13×107 succinate b ● ●
a alternative candidates for metabomatching exist (S1 Fig)
b additional candidates match to other non-targeted traits that also associate with SNP (S1 Fig)
Chr/Position: Chromosomal location of the lead SNP according to the human reference genome (GRCh37). EA/EAF: Effect allele and frequency. Trait or
pairwise ratio: Tested metabolic trait (chemical shift). In case of ratios, the trait that drives the association (i.e., shows the stronger association signal) is
named ﬁrst. N: Number of samples where both genotype and phenotype data were available for the tested SNP/metabolic trait pair. beta’: beta’ is deﬁned
as 10beta-1 where beta depicts the relative effect size representing the slope of the regression line in the linear model when using log10-scaled metabolic
traits and the occurrence of the SNP’s minor allele (coded as 0,1, and 2). Thus, beta’ describes the relative difference per minor allele copy for non-scaled
metabolic traits in comparison to the estimated mean of the metabolic trait in the major homozygote test subjects. P-gain: Deﬁned as min(P(M1)/P(M1/M2),
P(M2)/P(M1/M2)), where M1 and M2 represent the two traits of which the ratio M1/M2 is built. Metabomatching: Annotation of the non-targeted metabolic
trait at the given chemical shift as suggested by metabomatching (S1 Fig). Replicated: SNP/metabolic trait pair was replicated in KORA F4 (P <
1.32×10−3) (S2 Table). Targeted: SNP or proxy in LD is also associated with a targeted metabolic trait (P < 3.25×10−12) (Table 1).
doi:10.1371/journal.pgen.1005487.t002
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the metabotype. Furthermore, non-targeted metabolic traits that exhibit significant association
signals have to be assigned to distinct metabolites. In our study, we implemented algorithmic
approaches for both the locus-to-gene mapping and the assignment of non-targeted metabolic
features.
As the first step in the candidate gene selection, we assigned the significantly associated
SNPs to distinct loci using a physical distance threshold of 1Mb. Assigning variants within a
locus to one of the covered genes based only on proximity or plausibility ignores haploblock
structure and existing regulatory information for the SNPs such as expression quantitative trait
loci (eQTL). To take such information into account and to achieve an unbiased selection of
candidate genes, we collected evidence for each significantly associated SNP and its proxies in
strong linkage disequilibrium (LD) using the SNiPA web server [51]. For each locus, we
received a list of candidate genes that are linked to one or more associated variants (or a proxy
in LD). Thereby, genes are linked via genomic proximity (i.e., if any of the variants is located
within the candidate gene or is in close proximity), via eQTL associations (i.e., if any of the var-
iants is associated with expression levels of the gene in a previous eQTL study), or via regula-
tory element association (i.e., if any of the variants is contained in a promoter/enhancer/
repressor element that is associated with the gene). Moreover, missense variants or known
pathogenic variants in the locus are considered to provide additional types of evidence for the
linked genes. We finally assigned the locus to the gene with the strongest functional evidence
(i.e., the gene showing the highest number of different types of evidences (max. 5) among the
Fig 3. Loci with associated urinary metabolic traits and their overlap with previous mGWAS in blood
and urine.We identified and replicated genome-wide significant associations between metabolic traits and
genetic variants in 22 genetic loci (named after the most likely causative gene). Three loci could only be
identified using targeted metabolic traits, while 7 loci were exclusively discovered with non-targeted traits. 12
loci were identified using both targeted and non-targeted approaches. Loci with hitherto unknown
associations with urinary metabolic traits are highlighted (totaling 15). We identified and replicated significant
associations in 7 of the 11 loci that were reported in previous mGWAS in urine [5, 10–12]. We also discovered
significant associations of the ABO locus (marked with an asterisk) with non-targeted traits, but this locus
could not be replicated in KORA F4. When compared to previous mGWAS in blood, we find 14 loci that
display associations with metabolic traits in both urine and blood [1, 4, 6–8, 14–24].
doi:10.1371/journal.pgen.1005487.g003
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 8 / 28
T
ab
le
3.
T
w
en
ty
-t
w
o
id
en
tif
ie
d
an
d
re
p
lic
at
ed
lo
ci
an
d
th
ei
r
o
ve
rl
ap
w
it
h
as
so
ci
at
io
n
s
to
m
et
ab
o
lic
tr
ai
ts
an
d
cl
in
ic
al
p
h
en
o
ty
p
es
.
L
o
cu
s
A
ss
o
ci
at
ed
tr
ai
ts
L
o
cu
s
C
an
d
id
at
e
g
en
es
L
ea
d
S
N
P
s
T
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
N
o
n
-t
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
O
th
er
m
G
W
A
S
in
u
ri
n
e
O
th
er
m
G
W
A
S
in
b
lo
o
d
C
lin
ic
al
p
h
en
o
ty
p
es
C
o
m
m
en
t
F
u
n
ct
io
n
al
m
at
ch
N
A
T8
,A
LM
S
1,
D
U
S
P
11
,
S
TA
M
B
P
rs
10
17
84
09
b
N
-a
ce
ty
la
sp
ar
ta
te
d
%
N
-a
ce
ty
la
te
d
co
m
po
un
ds
%
[5
,1
1,
12
]
N
-a
ce
ty
lo
rn
ith
in
e
&
[6
,2
1,
25
],
cr
ea
tin
in
e
&
[1
9]
,2
-a
m
in
oo
ct
an
oi
c
ac
id
(p
re
v.
un
kn
ow
n
X
-1
25
10
)
&
[8
,
21
],
un
kn
ow
n
X
-1
17
87
%
[2
5]
,
un
kn
ow
n
X
-1
20
93
%
[2
1]
,u
nk
no
w
n
X
-1
34
77
&
[2
1]
ch
ro
ni
c
ki
dn
ey
di
se
as
e
e
[1
9,
26
],
gl
om
er
ul
ar
ﬁ
ltr
at
io
n
ra
te
e
[2
7]
N
A
T8
is
hi
gh
ly
ex
pr
es
se
d
in
ki
dn
ey
.
T
hi
s
ge
ne
pu
ta
tiv
el
y
en
co
de
s
an
N
-
ac
et
yl
tr
an
sf
er
as
e.
T
he
as
so
ci
at
io
n
of
th
is
lo
cu
s
w
ith
N
-a
ce
ty
la
te
d
L-
as
pa
rt
at
e
m
at
ch
es
th
e
en
zy
m
at
ic
fu
nc
tio
n.
●
H
IB
C
H
rs
13
00
68
33
b
un
kn
ow
n
N
M
R
tr
ai
t(
ra
tio
)
%
H
IB
C
H
en
co
de
s
3-
hy
dr
ox
yi
so
bu
ty
ry
l-
C
oA
hy
dr
ol
as
e.
H
IB
C
H
is
lin
ke
d
to
H
IB
C
H
de
ﬁ
ci
en
cy
(M
IM
25
06
20
),
w
hi
ch
ca
n
le
ad
to
ne
ur
od
eg
en
er
at
io
n
(O
rp
ha
N
et
88
63
9)
.
C
P
S
1
rs
71
5
a
,b
cr
ea
tin
e
%
,g
ly
ci
ne
(+
8
ra
tio
s)
%
cr
ea
tin
e
%
,g
ly
ci
ne
%
N
-a
ce
ty
lg
ly
ci
ne
%
[2
1]
,b
et
ai
ne
&
[2
1]
,c
ar
ni
tin
e
&
[2
1]
,c
re
at
in
e
%
[2
1,
28
],
ﬁ
br
io
ng
en
&
[1
5]
,g
lu
ta
ro
yl
gl
yc
in
e
%
[6
,1
4,
21
,2
2,
24
,2
5,
28
],
gl
yc
in
e/
P
C
ae
C
38
:2
%
[4
],
H
D
L
ch
ol
es
te
ro
l&
[1
7]
,h
om
oa
rg
in
in
e
%
[2
9]
,h
om
oc
ys
te
in
e
%
[3
0]
,
py
ro
gl
ut
am
in
e
&
[2
1]
,s
er
in
e
%
[2
1]
,
un
kn
ow
n
X
-0
89
88
%
[2
1]
ch
ro
ni
c
ki
dn
ey
di
se
as
e
e
[2
6]
,
ne
on
at
al
pu
lm
on
ar
y
hy
pe
rt
en
si
on
f
[3
1]
C
P
S
1
is
hi
gh
ly
ex
pr
es
se
d
in
liv
er
.I
t
en
co
de
s
a
m
ito
ch
on
dr
ia
lc
ar
ba
m
oy
l
ph
os
ph
at
e
sy
nt
he
ta
se
th
at
ge
ne
ra
te
s
ca
rb
am
oy
lp
ho
sp
ha
te
fr
om
am
m
on
ia
an
d
bi
ca
rb
on
at
e.
C
P
S
1
de
ﬁ
ci
en
cy
ca
us
es
H
yp
er
am
m
on
em
ia
(M
IM
23
73
00
).
E
xc
es
s
am
m
on
ia
co
ul
d
be
co
nv
er
te
d
to
gl
yc
in
e
vi
a
th
e
gl
yc
in
e
cl
ea
va
ge
co
m
pl
ex
(s
ee
m
ai
n
te
xt
).
●
A
G
X
T
rs
67
48
73
4
b
α
-k
et
oi
so
va
le
ra
te
d
%
un
kn
ow
n
X
-1
25
56
%
[2
1]
A
G
X
T
is
an
al
an
in
e-
gl
yo
xy
la
te
am
in
ot
ra
ns
fe
ra
se
,w
hi
ch
is
hi
gh
ly
ex
pr
es
se
d
in
liv
er
.T
he
en
co
de
d
pr
ot
ei
n
is
al
so
hi
gh
ly
lo
ca
liz
ed
in
liv
er
.A
G
X
T
is
lin
ke
d
to
ty
pe
1
H
yp
er
ox
al
ur
ia
,w
hi
ch
ca
n
ca
us
e
re
na
lf
ai
lu
re
(M
IM
25
99
00
).
X
Y
LB
rs
31
32
44
0
a
gl
yc
ol
at
e
%
is
ch
em
ic
st
ro
ke
e
,f
[3
2]
X
Y
LB
lik
el
y
en
co
de
s
a
xy
lu
lo
ki
na
se
th
at
ca
ta
ly
ze
s
D
-x
yl
ul
os
e
to
D
-x
yl
ul
os
e-
5-
ph
os
ph
at
e
[3
3]
.T
he
hi
gh
er
gl
yc
ol
at
e
co
nc
en
tr
at
io
n
m
ig
ht
in
di
ca
te
a
sw
itc
h
to
an
al
te
rn
at
iv
e
xy
lu
lo
se
pa
th
w
ay
vi
a
ph
os
ph
of
ru
ct
ok
in
as
e
(P
FK
),
as
gl
yc
ol
at
e
an
d
re
la
te
d
m
et
ab
ol
ite
s
(g
ly
ox
yl
at
e,
ox
al
at
e)
ar
e
do
w
ns
tr
ea
m
pr
od
uc
ts
of
th
e
re
ac
tio
n
ca
ta
ly
ze
d
by
P
FK
(s
ee
m
ai
n
te
xt
).
M
et
ab
ol
ic
pr
oﬁ
le
s
of
pa
tie
nt
s
w
ith
ce
re
br
al
in
fa
rc
tio
n
sh
ow
si
gn
iﬁ
ca
nt
ly
el
ev
at
ed
le
ve
ls
of
gl
yc
ol
at
e
[3
4]
.
●
S
LC
6A
20
,
C
C
R
1,
C
C
R
3,
C
C
R
9,
LI
M
D
rs
17
27
94
37
a
,b
N
,N
-d
im
et
hy
lg
ly
ci
ne
(+
10
ra
tio
s)
&
N
,N
-d
im
et
hy
lg
ly
ci
ne
&
N
,N
-d
im
et
hy
lg
ly
ci
ne
/
al
an
in
e
&
[1
0]
py
ro
gl
ut
am
in
e
%
[2
1]
,u
nk
no
w
n
X
-
11
31
5
&
[2
1]
Im
in
og
ly
ci
nu
ria
f
[3
5]
,
H
yp
er
gl
yc
in
ur
ia
f
[3
5]
S
LC
6A
20
en
co
de
s
th
e
S
IT
1
tr
an
sp
or
te
r
fo
r
im
in
o
ac
id
s
an
d
N
-m
et
hy
la
te
d
am
in
o
ac
id
s.
S
LC
6A
20
is
lin
ke
d
to
H
yp
er
gl
yc
in
ur
ia
an
d
Im
in
og
ly
ci
nu
ria
(M
IM
13
85
00
,M
IM
24
26
00
).
●
TK
T
c ,
P
R
K
C
D
,
G
LT
8D
1
rs
46
87
71
7
b
gl
uc
on
at
e
d
%
er
yt
hr
on
at
e/
ph
os
ph
at
e
%
[2
1]
TK
T
en
co
de
s
a
tr
an
sk
et
ol
as
e
th
at
co
nn
ec
ts
th
e
pe
nt
os
e
ph
os
ph
at
e
pa
th
w
ay
to
gl
yc
ol
ys
is
.P
R
K
C
D
is
lin
ke
d
to
au
to
im
m
un
e
di
se
as
es
(M
IM
61
55
59
,
O
rp
ha
N
et
30
03
45
).
E
TN
P
P
L
c ,
C
O
L2
5A
1
rs
56
04
38
87
a
,r
s7
43
78
90
b
et
ha
no
la
m
in
e
&
et
ha
no
la
m
in
e
&
E
TN
P
P
L
is
hi
gh
ly
ex
pr
es
se
d
in
br
ai
n
an
d
liv
er
.T
he
ge
ne
en
co
de
s
an
et
ha
no
la
m
in
e-
ph
os
ph
at
e-
ph
os
ph
ol
ya
se
.E
th
an
ol
am
in
e
is
th
e
di
re
ct
pr
ec
ur
so
r
of
et
ha
no
la
m
in
e-
ph
os
ph
at
e
(s
ee
m
ai
n
te
xt
).
●
(C
on
tin
ue
d
)
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 9 / 28
T
ab
le
3.
(C
on
tin
ue
d
)
L
o
cu
s
A
ss
o
ci
at
ed
tr
ai
ts
L
o
cu
s
C
an
d
id
at
e
g
en
es
L
ea
d
S
N
P
s
T
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
N
o
n
-t
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
O
th
er
m
G
W
A
S
in
u
ri
n
e
O
th
er
m
G
W
A
S
in
b
lo
o
d
C
lin
ic
al
p
h
en
o
ty
p
es
C
o
m
m
en
t
F
u
n
ct
io
n
al
m
at
ch
S
LC
6A
19
c ,
S
LC
6A
18
rs
11
13
36
65
a
, rs
11
75
02
11
b
hi
st
id
in
e
(+
3
ra
tio
s)
&
,t
yr
os
in
e
(+
1
ra
tio
)
&
ty
ro
si
ne
&
S
LC
6A
18
an
d
S
LC
6A
19
en
co
de
tr
an
sp
or
te
rs
fo
r
ne
ut
ra
la
m
in
o
ac
id
s
in
ki
dn
ey
.B
ot
h
ge
ne
s
ar
e
lin
ke
d
to
Im
in
og
ly
ci
nu
ria
[M
IM
24
26
00
,
O
rp
ha
N
et
42
06
2]
;S
LC
6A
19
is
lin
ke
d
to
H
yp
er
gl
yc
in
ur
ia
(M
IM
13
85
00
)
an
d
H
ar
tn
up
di
so
rd
er
(M
IM
23
45
00
).
A
G
X
T2
,
D
N
A
JC
21
,
P
R
LR
,R
A
D
1
rs
37
36
9
a
,b
3-
am
in
oi
so
bu
ty
ra
te
%
3-
am
in
oi
so
bu
ty
ra
te
%
3-
am
in
oi
so
bu
ty
ra
te
%
[5
,1
0,
12
]
3-
am
in
oi
so
bu
ty
ra
te
%
[2
8]
,
sy
m
m
et
ric
/a
sy
m
m
et
ric
di
m
et
hy
la
rg
in
in
e
%
[2
0]
,
ho
m
oa
rg
in
in
e
&
[2
9]
he
ar
tr
at
e
va
ria
bi
lit
y
e
[2
0]
A
G
X
T2
ex
pr
es
si
on
is
en
ric
he
d
in
br
ai
n
an
d
liv
er
.I
tc
at
al
yz
es
th
e
bi
os
yn
th
es
is
of
3-
am
in
oi
so
bu
ty
ra
te
.T
he
no
n-
sy
no
ny
m
ou
s
va
ria
nt
rs
37
36
9
is
m
os
t
lik
el
y
ca
us
at
iv
e
fo
r
B
et
a-
am
in
oi
so
bu
ty
ric
ac
id
ur
ia
(M
IM
21
01
0)
[1
0,
36
].
●
D
M
G
D
H
,
B
H
M
T,
A
R
S
B
rs
64
53
42
9
a
,
rs
64
53
42
7
b
N
,N
-d
im
et
hy
lg
ly
ci
ne
(+
5
ra
tio
s)
%
N
,N
-d
im
et
hy
lg
ly
ci
ne
d
%
be
ta
in
e
&
[2
1]
,d
im
et
hy
lg
ly
ci
ne
%
[2
4,
28
],
se
le
ni
um
%
[1
8]
D
M
G
D
H
ex
pr
es
si
on
is
hi
gh
ly
en
ric
he
d
in
ki
dn
ey
an
d
liv
er
,a
nd
so
is
th
e
ge
ne
pr
od
uc
t.
D
M
G
D
H
en
co
de
s
di
m
et
hy
lg
ly
ci
ne
de
hy
dr
og
en
as
e.
D
M
G
D
H
de
ﬁ
ci
en
cy
ca
us
es
ﬁ
sh
-li
ke
bo
dy
od
or
(M
IM
60
58
50
).
In
th
e
sa
m
e
lo
cu
s,
B
H
M
T
ca
ta
ly
ze
s
N
,N
-
di
m
et
hy
lg
ly
ci
ne
an
d
L-
m
et
hi
on
in
e
to
be
ta
in
e
an
d
ho
m
oc
ys
te
in
e
(E
C
2.
1.
1.
5)
.
●
S
LC
36
A
2
rs
38
46
71
0
a
,b
gl
yc
in
e/
ci
tr
at
e
&
gl
yc
in
e
&
S
LC
36
A
2
ex
pr
es
si
on
is
en
ric
he
d
in
ki
dn
ey
.T
he
ge
ne
en
co
de
s
a
tr
an
sp
or
te
r
(P
A
T2
)
fo
r
sm
al
la
m
in
o
ac
id
s
(in
cl
ud
in
g
gl
yc
in
e)
.L
ik
e
S
LC
6A
20
,S
LC
36
A
2
is
lin
ke
d
to
H
yp
er
gl
yc
in
ur
ia
an
d
Im
in
og
ly
ci
nu
ria
(M
IM
13
85
00
,M
IM
24
26
00
).
●
N
A
T2
,A
S
A
H
1,
P
C
M
1
rs
14
95
74
3
a
,
rs
35
24
63
81
b
fo
rm
at
e
(+
8
ra
tio
s)
%
fo
rm
at
e
%
,b
ut
yr
at
e
d
%
,
ac
et
yl
ca
rn
iti
ne
d
%
,N
-
ac
et
yl
pu
tr
es
ci
ne
d
%
,τ
-
m
et
hy
lh
is
tid
in
e
d
&
,
1,
3-
di
m
et
hy
lu
ra
te
d
&
fo
rm
at
e/
su
cc
in
at
e
%
[1
0]
,u
nk
no
w
n
N
M
R
tr
ai
t%
[1
2]
4-
ac
et
am
id
ob
ut
an
oa
te
%
[2
1]
,
1-
m
et
hy
lu
ra
te
&
[2
1]
,
1-
m
et
hy
lx
an
th
in
e
&
[2
1]
,t
ot
al
ch
ol
er
st
er
ol
%
[1
7,
37
],
tr
ig
ly
ce
rid
es
%
[1
7,
37
]
bl
ad
de
r
ca
nc
er
e
[3
8,
39
],
dr
ug
re
sp
on
se
(s
lo
w
ac
et
yl
at
io
n)
f
[4
0–
43
]
N
A
T2
en
co
de
s
an
ar
yl
am
in
e
N
-
ac
et
yl
tr
an
sf
er
as
e.
N
A
T2
is
lin
ke
d
to
sp
ee
d
of
ac
et
yl
at
io
n
(M
IM
24
34
00
).
●
G
LD
C
rs
17
55
61
5
a
gl
yc
in
e/
al
an
in
e
%
G
LD
C
en
co
de
s
th
e
m
ito
ch
on
dr
ia
l
gl
yc
in
e
de
hy
dr
ox
yg
en
as
e
(d
ec
ar
bo
xy
la
tin
g)
,w
hi
ch
is
pa
rt
of
th
e
gl
yc
in
e
cl
ea
va
ge
sy
st
em
.M
ut
at
io
ns
in
G
LD
C
ca
n
ca
us
e
gl
yc
in
e
en
ce
ph
al
op
at
hy
(M
IM
60
58
99
).
G
LD
C
ex
pr
es
si
on
is
en
ric
he
d
in
ki
dn
ey
an
d
liv
er
.
●
P
Y
R
O
X
D
2,
H
P
S
1
rs
11
59
88
67
b
tr
im
et
hy
la
m
in
e
d
&
tr
im
et
hy
la
m
in
e
&
[5
,
11
,1
2]
,u
nk
no
w
n
N
M
R
tr
ai
t&
[1
2]
1-
m
et
hy
l-2
-p
ip
er
id
in
e
ca
rb
ox
yl
ic
ac
id
(p
re
v.
un
kn
ow
n
X
-1
20
92
)
&
[8
,2
1]
,
ca
pr
ol
ac
ta
m
[1
6]
,a
sy
m
m
et
ric
di
m
et
hy
la
rg
in
in
e
&
[2
8]
,
di
m
et
hy
la
m
in
e
&
[5
],
un
kn
ow
n
N
M
R
tr
ai
t&
[2
2]
,u
nk
no
w
n
X
-1
20
93
&
[8
,
21
]
H
er
m
an
sk
y-
P
ud
la
k
sy
nd
ro
m
e
If
[4
4]
P
Y
R
O
X
D
2
co
de
s
fo
r
“p
yr
id
in
e
nu
cl
eo
tid
e-
di
su
lp
hi
de
ox
id
or
ed
uc
ta
se
do
m
ai
n
2”
.
S
LC
6A
13
rs
11
06
21
02
a
,b
3-
am
in
oi
so
bu
ty
ra
te
(+
1
ra
tio
)
&
3-
am
in
oi
so
bu
ty
ra
te
d
&
3-
am
in
oi
so
bu
ty
ra
te
&
[2
8]
,
py
ro
gl
ut
am
in
e
&
[2
1]
ch
ro
ni
c
ki
dn
ey
di
se
as
e
e
[2
6]
S
LC
6A
13
is
hi
gh
ly
ex
pr
es
se
d
in
ki
dn
ey
.
It
en
co
de
s
G
A
T2
th
at
tr
an
sp
or
ts
be
ta
in
e,
w
hi
ch
se
rv
es
as
an
os
m
ol
yt
e
in
ki
dn
ey
,a
nd
ga
m
m
a-
am
in
ob
ut
yr
ic
ac
id
(G
A
B
A
).
S
LC
6A
13
m
ig
ht
al
so
be
a
tr
an
sp
or
te
r
fo
r
3-
am
in
oi
so
bu
ty
ra
te
,
w
hi
ch
ha
s
a
si
m
ila
r
ch
em
ic
al
st
ru
ct
ur
e
to
be
ta
in
e
an
d
G
A
B
A
.
(C
on
tin
ue
d
)
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 10 / 28
T
ab
le
3.
(C
on
tin
ue
d
)
L
o
cu
s
A
ss
o
ci
at
ed
tr
ai
ts
L
o
cu
s
C
an
d
id
at
e
g
en
es
L
ea
d
S
N
P
s
T
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
N
o
n
-t
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
O
th
er
m
G
W
A
S
in
u
ri
n
e
O
th
er
m
G
W
A
S
in
b
lo
o
d
C
lin
ic
al
p
h
en
o
ty
p
es
C
o
m
m
en
t
F
u
n
ct
io
n
al
m
at
ch
H
P
D
,W
D
R
66
,
P
S
M
D
9
rs
47
60
09
9
a
,
rs
19
16
33
3
b
2-
hy
dr
ox
yi
so
bu
ty
ra
te
&
2-
hy
dr
ox
yi
so
bu
ty
ra
te
&
2-
hy
dr
ox
yi
so
bu
ty
ra
te
&
[1
0,
12
]
2-
hy
dr
ox
yi
so
bu
ty
ra
te
&
[2
1]
T
yr
os
in
em
ia
f
[4
5]
,
H
aw
ki
ns
ur
ia
f
[4
5]
,
H
P
D
de
ﬁ
ci
en
cy
f
[4
5]
T
he
H
P
D
ge
ne
pr
od
uc
tc
at
al
yz
es
4-
hy
dr
ox
yp
he
ny
lp
yr
uv
at
e
to
ho
m
og
en
tis
at
e.
2-
hy
dr
ox
yi
so
bu
ty
ra
te
m
ay
be
re
la
te
d
to
br
an
ch
ed
ch
ai
n
am
in
o
ac
id
de
gr
ad
at
io
n
m
et
ab
ol
ite
s.
H
P
D
is
lin
ke
d
to
ty
pe
3
T
yr
os
in
em
ia
(M
IM
27
67
10
)
an
d
H
aw
ki
ns
ur
ia
(M
IM
14
03
50
).
H
P
D
is
hi
gh
ly
ex
pr
es
se
d
an
d
lo
ca
liz
ed
in
liv
er
an
d
ki
dn
ey
.
A
C
S
M
3
c ,
A
C
S
M
1
rs
11
64
50
02
b
3-
hy
dr
ox
yi
so
va
le
ra
te
%
T
he
A
C
S
M
3
ge
ne
pr
od
uc
t(
al
ia
s
S
a
or
S
A
H
)
is
an
ac
yl
-C
oA
sy
nt
he
ta
se
m
ed
iu
m
-c
ha
in
fa
m
ily
m
em
be
r.
“I
so
bu
ty
ra
te
is
th
e
m
os
tp
re
fe
rr
ed
fa
tty
ac
id
am
on
g
C
2-
C
6
fa
tty
ac
id
s
fo
r
S
a
pr
ot
ei
n.
”
[4
6]
T
o
le
ss
er
ex
te
nt
,A
C
S
M
3
sh
ow
s
su
bs
tr
at
e
sp
ec
iﬁ
ci
ty
fo
r
th
e
C
5
fa
tty
ac
id
is
ov
al
er
at
e
[4
6]
.I
ti
s
es
tim
at
ed
th
at
A
C
S
M
3
ac
ts
on
“a
ci
ds
fr
om
C
4
to
C
11
an
d
on
th
e
co
rr
es
po
nd
in
g
3-
hy
dr
ox
y
(.
..
)
un
sa
tu
ra
te
d
ac
id
s”
(U
ni
P
ro
tQ
53
F
Z
2)
.
A
C
S
M
3
is
su
sp
ec
te
d
to
be
a
ris
k
lo
cu
s
fo
r
ov
er
w
ei
gh
ta
nd
hy
pe
rt
en
si
on
(M
IM
14
55
05
).
●
S
LC
5A
11
,
A
R
H
G
A
P
17
,
TN
R
C
6A
rs
17
70
29
12
b
m
yo
-in
os
ito
ld
%
m
yo
-in
os
ito
l&
[2
1]
,s
cy
llo
-in
os
ito
l&
[2
1]
S
LC
5A
11
is
sh
or
tf
or
so
lu
te
ca
rr
ie
r
fa
m
ily
5
so
di
um
/m
yo
-in
os
ito
l
tr
an
sp
or
te
r,
m
em
be
r
11
(s
ee
m
ai
n
te
xt
).
●
P
N
M
T,
M
E
D
1,
P
P
P
1R
B
,
S
TA
R
D
3
rs
72
19
01
4
a
,
rs
80
69
45
1
b
hi
st
id
in
e
(+
1
ra
tio
)
&
,
ty
ro
si
ne
&
ty
ro
si
ne
&
H
D
L
ch
ol
es
te
ro
l&
[1
7,
37
]
rh
eu
m
at
oi
d
ar
th
rit
is
e
[4
7]
,r
ed
uc
ed
P
N
M
T
ac
tiv
ity
f
[4
8]
P
N
M
T
co
de
s
fo
r
ph
en
yl
et
ha
no
la
m
in
e
N
-m
et
hy
ltr
an
sf
er
as
e
an
d
is
pa
rt
of
ty
ro
si
ne
m
et
ab
ol
is
m
(E
C
2.
1.
1.
28
).
●
S
LC
7A
9,
C
19
or
f4
0,
C
E
P
89
,
R
H
P
N
2,
TD
R
D
12
rs
72
47
97
7
a
ly
si
ne
(+
8
ra
tio
s)
%
ly
si
ne
/v
al
in
e
%
[1
0]
,
ly
si
ne
%
[1
2]
ho
m
oc
itr
ul
lin
e
&
[2
1]
,N
G
-
m
on
om
et
hy
l-a
rg
in
in
e
&
[2
8]
ch
ro
ni
c
ki
dn
ey
di
se
as
e
e
[2
6]
S
LC
7A
9
is
a
tr
an
sp
or
te
r
fo
r
cy
st
ei
ne
an
d
ne
ut
ra
la
nd
di
ba
si
c
am
in
o
ac
id
s.
Ly
si
ne
is
a
di
ba
si
c
am
in
o
ac
id
an
d
m
ig
ht
th
us
be
a
su
bs
tr
at
e
of
S
LC
7A
9.
S
LC
7A
9
is
lin
ke
d
to
C
ys
tin
ur
ia
(M
IM
22
01
00
).
●
(C
on
tin
ue
d
)
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 11 / 28
T
ab
le
3.
(C
on
tin
ue
d
)
L
o
cu
s
A
ss
o
ci
at
ed
tr
ai
ts
L
o
cu
s
C
an
d
id
at
e
g
en
es
L
ea
d
S
N
P
s
T
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
N
o
n
-t
ar
g
et
ed
m
et
ab
o
lo
m
ic
s
[t
h
is
st
u
d
y]
O
th
er
m
G
W
A
S
in
u
ri
n
e
O
th
er
m
G
W
A
S
in
b
lo
o
d
C
lin
ic
al
p
h
en
o
ty
p
es
C
o
m
m
en
t
F
u
n
ct
io
n
al
m
at
ch
S
LC
13
A
3,
S
LC
2A
10
rs
94
12
06
a
,b
su
cc
in
at
e/
ci
tr
at
e
%
su
cc
in
at
e
%
S
LC
13
A
3
is
a
hi
gh
-a
fﬁ
ni
ty
di
ca
rb
ox
yl
at
e
tr
an
sp
or
te
r
th
at
m
ed
ia
te
s
th
e
tr
an
sp
or
to
fs
uc
ci
na
te
[4
9]
.I
ti
s
hi
gh
ly
ex
pr
es
se
d
in
ki
dn
ey
.
●
a
S
N
P
w
ith
th
e
st
ro
ng
es
ta
ss
oc
ia
tio
n
to
ta
rg
et
ed
m
et
ab
ol
ic
tr
ai
ts
(“
le
ad
S
N
P
”)
b
S
N
P
w
ith
th
e
st
ro
ng
es
ta
ss
oc
ia
tio
n
to
no
n-
ta
rg
et
ed
m
et
ab
ol
ic
tr
ai
ts
c
m
an
ua
lly
ad
de
d
to
th
e
lis
to
fm
os
tp
la
us
ib
le
ca
nd
id
at
e
ge
ne
s
de
riv
ed
by
ev
id
en
ce
-b
as
ed
se
le
ct
io
n
d
ad
di
tio
na
lc
an
di
da
te
s
m
at
ch
to
ot
he
r
no
n-
ta
rg
et
ed
tr
ai
ts
th
at
al
so
as
so
ci
at
e
w
ith
th
e
le
ad
S
N
P
e
re
su
lts
fr
om
G
W
A
S
(P
<
5.
0×
10
−
8
)
f
m
ut
at
io
ns
de
te
rm
in
ed
in
cl
in
ic
al
st
ud
ie
s
F
or
ea
ch
lo
cu
s,
w
e
se
le
ct
ed
al
lv
ar
ia
nt
s
th
at
di
sp
la
ye
d
ge
no
m
e-
w
id
e
si
gn
iﬁ
ca
nt
as
so
ci
at
io
n
si
gn
al
s
to
m
et
ab
ol
ic
tr
ai
ts
in
th
e
S
H
IP
-0
co
ho
rt
.W
e
ad
de
d
th
ei
r
pr
ox
y
va
ria
nt
s
in
LD
(r
2

0.
8;
ba
se
d
on
10
00
ge
no
m
es
pr
oj
ec
td
at
a
[5
0,
51
])
.T
he
se
va
ria
nt
se
ts
w
er
e
us
ed
fo
r
th
e
se
le
ct
io
n
of
ca
nd
id
at
e
ge
ne
s
an
d
th
e
co
m
pa
ris
on
w
ith
as
so
ci
at
io
n
re
su
lts
fr
om
ot
he
r
st
ud
ie
s.
C
an
d
id
at
e
g
en
es
:
se
le
ct
io
n
of
ge
ne
s
ba
se
d
on
va
ria
nt
ev
id
en
ce
(g
en
es
hi
to
r
cl
os
e-
by
,e
Q
T
L,
po
te
nt
ia
lly
re
gu
la
to
ry
ef
fe
ct
s,
or
m
is
se
ns
e
va
ria
nt
s)
(S
3
T
ab
le
).
G
en
es
w
ith
th
e
hi
gh
es
te
vi
de
nc
e
co
un
ts
ar
e
lis
te
d.
G
en
es
w
ith
th
e
m
os
tp
la
us
ib
le
bi
oc
he
m
ic
al
re
la
tio
n
to
th
e
as
so
ci
at
ed
tr
ai
ta
re
hi
gh
lig
ht
ed
in
bo
ld
ty
pe
fa
ce
.A
ss
o
ci
at
ed
tr
ai
ts
:T
ar
ge
te
d/
no
n-
ta
rg
et
ed
m
et
ab
ol
om
ic
s:
tr
ai
ts
th
at
di
sp
la
y
ge
no
m
e-
w
id
e
si
gn
iﬁ
ca
nt
as
so
ci
at
io
n
si
gn
al
s
in
S
H
IP
-0
.T
he
ar
ro
w
s
in
di
ca
te
w
he
th
er
th
e
tr
ai
ti
nc
re
as
es
(%
)
or
de
cr
ea
se
s
(&
)
pe
r
co
py
of
th
e
ef
fe
ct
al
le
le
.F
or
no
n-
ta
rg
et
ed
tr
ai
ts
,t
he
m
os
tp
la
us
ib
le
m
et
ab
ol
ite
ca
nd
id
at
es
ac
co
rd
in
g
to
m
et
ab
om
at
ch
in
g
ar
e
gi
ve
n.
O
th
er
m
G
W
A
S
in
u
ri
n
e/
b
lo
o
d
:
m
et
ab
ol
ic
tr
ai
ts
th
at
w
er
e
pr
ev
io
us
ly
fo
un
d
to
be
as
so
ci
at
ed
w
ith
a
lo
cu
s
va
ria
nt
.T
he
ar
ro
w
s
in
di
ca
te
th
e
di
re
ct
io
na
lit
y
of
th
e
ef
fe
ct
fo
r
th
e
re
po
rt
ed
ef
fe
ct
al
le
le
(w
he
re
av
ai
la
bl
e)
.C
lin
ic
al
p
h
en
o
ty
p
es
:
ov
er
la
p
w
ith
va
ria
nt
s
fo
un
d
to
be
as
so
ci
at
ed
w
ith
cl
in
ic
al
tr
ai
ts
.C
o
m
m
en
t:
G
en
e
ex
pr
es
si
on
ra
te
s
w
er
e
ta
ke
n
fr
om
th
e
Ill
um
in
a
B
od
y
M
ap
2.
0
(S
4
T
ab
le
).
P
ro
te
in
lo
ca
liz
at
io
ns
w
er
e
ta
ke
n
fr
om
th
e
H
um
an
P
ro
te
in
A
tla
s
(v
er
si
on
12
)
[5
2]
.F
or
ge
ne
s
lin
ke
d
to
cl
in
ic
al
tr
ai
ts
,w
e
pr
ov
id
e
O
M
IM
or
O
rp
ha
N
et
ac
ce
ss
io
n
nu
m
be
rs
if
av
ai
la
bl
e.
F
u
n
ct
io
n
al
m
at
ch
:I
nd
ic
at
es
w
hi
ch
as
so
ci
at
io
ns
ex
hi
bi
ta
so
un
d
bi
ol
og
ic
al
lin
k
be
tw
ee
n
ge
ne
fu
nc
tio
n
an
d
th
e
bi
oc
he
m
ic
al
na
tu
re
of
th
e
as
so
ci
at
ed
m
et
ab
ol
ite
(s
).
do
i:1
0.
13
71
/jo
ur
na
l.p
ge
n.
10
05
48
7.
t0
03
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 12 / 28
candidate genes; see Methods). In case of ambiguous assignments, the gene with the most plau-
sible biological function was chosen. As an example, one locus contains a high number of SNPs
with strong associations with non-targeted traits corresponding to N-acetylated compounds.
These SNPs cover 12 different genes (see regional association plots in S2 Fig). The gene covered
by the highest number of SNPs is ALMS1. However, there are 3 more genes in this locus with
the same amount of functional evidence count as ALMS1 (S3 Table). One of these genes is
NAT8, which encodes an N-acetyltransferase. Since there is a biologically meaningful link
between the function of the NAT8 gene product and the associated metabolic traits, we anno-
tated this locus with NAT8 as the most likely candidate gene. According to our evidence-based
candidate genes assignment approach, the 23 loci map to the genes NAT8, HIBCH, CPS1,
AGXT, XYLB, SLC6A20, TKT, ETNPPL, SLC6A19, AGXT2, DMGDH, SLC36A2, NAT2, ABO,
GLDC, PYROXD2, SLC6A13, HPD, ACSM3, SLC5A11, PNMT, SLC7A9, and SLC13A3. S3
Table provides a complete list of candidate genes and the corresponding collected evidences.
For the identification of metabolites underlying non-targeted NMR traits, we used pseudo-
spectra that display the strength of associations of a given SNP across the complete NMR spec-
trum [12, 22]. If the association is strong enough, these “association spectra” often exhibit a
striking similarity to the reference NMR spectrum of the underlying metabolite(s). For the
present study, we applied the “metabomatching” method introduced by Rueedi et al. [12] to
perform an automated annotation of the association spectra for each genetic locus of interest.
For 19 of the 20 loci that display significant associations with non-targeted traits, metabo-
matching suggests plausible metabolite candidates matching signals present in the association
spectra (S1 Fig). For 10 of these 19 loci (CPS1, SLC6A20, ETNPPL, SLC6A19, AGXT2,
SLC36A2,HPD, ACSM3, PNMT, and SLC13A3), the match between the association signal and
the NMR spectrum of the candidate metabolite (as provided by the Urine Metabolome Data-
base [54]) is strong and unique, which makes the assignment of a metabolite identity to a non-
targeted trait unambiguous in these cases.
Replication
To replicate our findings, we used genotype data and urine samples from participants of the
KORA F4 cohort (N = 1,691). From recorded 1H NMR spectra of the urine samples, we derived
the targeted and non-targeted metabolic traits (metabolite concentrations, NMR spectral fea-
tures, and the respective pairwise ratios) as for the discovery study. For 14 of the 15 new loci
that show significant associations with targeted metabolic traits in the SHIP-0 data set, the top-
ranking SNP/metabolic trait association replicates in KORA F4 (S1 Table). For the SLC7A9
locus, the association with lysine/valine does not replicate, possibly due to the difficulty in
annotating lysine from the NMR spectra (> 75% missing values for lysine). However, the sec-
ond-best, still genome-wide significant association of the tested SNP with valine replicates. For
15 of 20 loci that display significant association signals in the GWAS with non-targeted traits,
we were able to replicate the best SNP/NMR trait association or, if this failed, the next, still sig-
nificant follow-up association (S2 Table). The failure to replicate the remaining 5 loci might be
due to the lower sample size in KORA, due to different fasting states of the subjects in the dif-
ferent cohorts, or due to a less perfect alignment of the NMR spectra, since we chose the same
FOCUS parameters for aligning SHIP and KORA spectra instead of treating them separately.
However, 4 of these 5 loci (ETNPPL, SLC6A19, DMGDH, PNMT) show also significant associa-
tions in the targeted SHIP-0 data set that replicate in the targeted KORA F4 data set (Table 1).
Out of the 23 loci identified in the discovery study, ABO is the only locus that could not be rep-
licated using either a targeted or a non-targeted metabolic trait in KORA F4, leaving 22 loci
that display stable associations with metabolic traits in urine.
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 13 / 28
Overlap with previous mGWAS in urine and blood
We evaluated each identified and replicated locus in the light of previously reported associa-
tions with metabolic phenotypes and clinical traits. To this end, we selected all SNPs within a
locus for which we found genome-wide significant associations with any urinary metabolic
trait in the SHIP-0 cohort. Furthermore, we added all bi-allelic variants from the 1000 genomes
project [50] (phase 1, version 3, European ancestry) that are in strong LD to these SNPs (r2
0.8).
For 15 of the 22 loci, no associations with urinary metabolic traits were reported so far
(HIBCH, CPS1, AGXT, XYLB, TKT, ETNPPL, SLC6A19, DMGDH, SLC36A2, GLDC, SLC6A13,
ACSM3, SLC5A11, PNMT, and SLC13A3) (Fig 3, Table 3). The remaining 7 loci were already
identified in our previous urine mGWAS (AGXT2,HPD, SLC7A9, SLC6A20, and NAT2) [10]
or in the studies by Nicholson et al. [5] and Rueedi et al. [12] (NAT8 and PYROXD2). For all 7
loci, both trait association and direction of the observed effect are consistent with the results
previously published.
We further compared our association results with those of published mGWAS with meta-
bolic traits in blood (P< 5×10−8), including all studies listed in the NHGRI GWAS catalog
[23] and other studies such as the mGWAS by Shin et al., which is based on metabolomics data
from the KORA F4 and TwinsUK cohorts [1, 4, 6–8, 14–22, 24]. In total, 14 loci show signifi-
cant associations with metabolic traits both in blood in one of these mGWAS and in urine in
our study (Fig 3, Table 3). For 3 of these 14 loci (SLC6A20, PNMT, AGXT), we consider the
associated metabolic traits in both media to be unrelated. In 5 cases (NAT2, NAT8, PYROXD2,
SLC7A9, TKT), the genetic association analyses identified different, but related metabolites
(i.e., the associated metabolites from urine and blood are either products/substrates of the
locus’ candidate gene product, or are biochemically converted within another known enzy-
matic reaction, or belong to the same metabolite class). In 6 cases, the associations target the
same metabolites in urine and blood (CPS1, AGXT2, DMGDH, SLC6A13,HPD, SLC5A11). For 5
of these 6 loci, the direction of the observed effect is the same, whereas for SLC5A11 (associated
withmyo-inositol), we observe an increase in urinary metabolite concentration per copy of the
effect allele, as opposed to decreased levels reported in blood (Table 3). For this locus, we addi-
tionally investigated whether the effects seen in blood and urine are directly coupled. To this end,
we made use ofmyo-inositol levels (normalized to circulating creatinine) measured through
mass spectrometry (MS) in blood serum samples of the same KORA F4 participants [6] that
form the replication cohort in this study. The ratio between the urinarymyo-inositol (this study)
and the serummyo-inositol levels shows an increase in association strength to the lead SNP in
SLC5A11 (rs17702912) by seven orders of magnitude in comparison to the association of urinary
myo-inositol alone (Purine< 1.95×10
−24, Pblood< 1.50×10
−4, Pratio< 2.43×10
−31).
Overlap with disease-associated variants and risk genes
For 11 loci, our mGWAS identified significantly associated variants for which either the same
variant or a proxy in strong LD was previously reported to be associated with clinical pheno-
types according to data from the NHGRI GWAS catalog [23] (P< 5×10−8), OMIM variation,
ClinVar [55], HGMD [56], or dbGaP [57]. Amongst others, these variants have been linked to
chronic kidney disease (NAT8, CPS1, SLC6A13, and SLC7A9), pulmonary hypertension
(CPS1), ischemic stroke (XYLB), Iminoglycinuria (SLC6A20), heart rate variability (AGXT2),
Hawkinsuria (HPD), and pharmacogenomically relevant acetylation phenotypes (NAT2)
(Table 3). In addition to these 11 loci with disease-associated variants, we found previously dis-
covered connections between clinical traits and the assigned candidate gene for another 7 loci
(HIBCH, AGXT, SLC6A19, DMGDH, SLC36A2, GLDC, ACSM3).
15 Novel Loci of Urinary Human Metabolic Individuality
PLOS Genetics | DOI:10.1371/journal.pgen.1005487 September 9, 2015 14 / 28
Discussion
In this study, we present the largest genome-wide association study with metabolic traits
(mGWAS) in urine to date. In addition to quadrupling the sample size compared to previous
mGWAS in urine, we analyzed both targeted traits (metabolite concentrations manually
derived from NMR spectra) and non-targeted traits (NMR spectral features).
Fifteen new genetic loci linked to urinary metabolic traits
In total, we identified 23 genetic loci with significant associations between genetic variants and
targeted or non-targeted metabolic traits in urine of SHIP-0 participants, 22 of which replicate
in the independent KORA F4 cohort. To the best of our knowledge, 15 loci have not been
linked to changes in the urine metabolome before. For the remaining 7 loci, our results are in
line with the results from previous mGWAS in urine [5, 10, 12] regarding both the associated
metabolic traits and the direction of the genetic effects (Table 3).
Targeted and non-targeted metabolomics are complementary
Though derived from the same NMR spectra, the list of GIMs identified with targeted traits
and non-targeted traits partly differ. Of the 22 genetic loci reported in this study, only 12 loci
were discovered in both targeted and non-targeted traits, whereas 7 loci show significant asso-
ciations only with non-targeted traits, and 3 only with targeted traits (Fig 3 and Table 3).
For the data set used in the targeted analysis, the NMR spectra were manually annotated to
identify and quantify the metabolites underlying the spectra. Involving human expert knowl-
edge usually allows metabolite identification with very high confidence and yields more precise
quantification, especially if signals of multiple metabolites overlap in the NMR spectrum. Fur-
thermore, a manual annotation can to some extent compensate for different experimental and
sample conditions, as alignment and pre-processing can be optimized for each spectrum indi-
vidually. As an example, lysine exhibits characteristic signals in the NMR spectral region
between δ = 1.68 and 1.76 ppm, which is often dominated by signals from a variety of addi-
tional metabolites, making the annotation of lysine a very difficult task. Thus, while lysine con-
centrations could be determined for 888 samples of the discovery cohort through manual
quantification and yielded a significant genetic association at SLC7A9, the non-targeted
approach did not capture any association signals for this locus.
However, a manual spectral annotation as performed in the targeted analysis is quite labori-
ous, which limits the number of quantifiable metabolites in large studies. This leads to a bias
towards a certain set of metabolites and, as a consequence, significant associations actually
present in the NMR data might be missed. Also, a manual annotation in general bears some
risk of annotator-induced bias [58]. As an automated method, the non-targeted analysis of
spectra has the potential to overcome some of the limitations of targeted analyses. Here, the
most prominent example is the PYROXD2 locus, where SNPs display exceptionally strong
associations (P< 1.0×10−307) to the NMR signal intensities at δ = 2.854 ppm. We could not
identify any significant associations within this locus using the targeted data. Thus, we assumed
that our set of targeted traits did not cover the metabolite(s) corresponding to these signals.
The challenge with genetically associated non-targeted traits lies in the lack of biochemical
interpretability. To facilitate the assignment of non-targeted NMR traits to chemical com-
pounds, we applied the metabomatching algorithm introduced by Rueedi et al. [12]. In case of
PYROXD2, metabomatching suggests that the associated NMR signals correspond to trimethy-
lamine. Thereby, the automated method replicates the findings of Nicholson et al. [5] where
the authors manually annotated the associated signals based on expert knowledge. In case of
our mGWAS with targeted traits, trimethylamine was not part of the metabolite panel and
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thus the association with PYROXD2 could only be discovered using non-targeted metabolic
traits in combination with the automated metabomatching processing. Of course, automated
annotation of non-targeted traits also has its limitations: the annotation through metabo-
matching relies on the association signals that genetic variants display over the NMR spectral
range (“association spectra”) as well as on the existence of the relevant reference metabolite
spectrum (see Methods and S1 Fig). In some cases, these association spectra are not meaningful
enough to allow an unambiguous assignment of non-targeted features to metabolites, or they
may be pointing to a metabolite not present in the reference set.
In summary, our study demonstrates that GWAS with NMR-determined metabolic traits
can benefit from a combined application of both targeted and non-targeted metabolomics. Our
results suggest that a targeted approach is better suited for the annotation of metabolites for
which the corresponding NMR signals are in regions with a plethora of other signals as in
some cases these signals cannot be resolved through non-targeted methods. Furthermore,
genetic associations with targeted traits appear to be more robust, since 5 of the 12 loci that dis-
play associations with both targeted and non-targeted traits clearly display stronger association
signals in the targeted data set (several orders of magnitude in case of the SLC6A20 locus;
Tables 1 and 2). However, the non-targeted metabolic traits provide a less biased view on the
metabolome, which in our case results in additional significantly associated genetic loci.
Functional metabolomics: from GIMs to testable hypotheses
Fifteen of the 22 identified and replicated loci show a plausible biochemical connection
between functionally annotated genes and their associated metabolic traits (Table 3). This is
similar to observations from previous mGWAS. For instance, Shin et al. reported biologically
meaningful links between metabolites and genetic loci for 101 of 145 GIMs [21]. In case of
genes with vague functional annotations, gene-metabolite associations from mGWAS provide
testable hypotheses for further gene characterization. As an example, Suhre et al. experimen-
tally confirmed the mGWAS driven hypothesis of SLC16A9 being a carnitine transporter [6].
Vice versa, with the help of mGWAS, the chemical structure of a non-targeted metabolic trait
was elucidated through the function of the associated gene [8].
Another prominent finding of previous mGWAS is the overlap between disease relevant
genetic variants and variants associated with metabolic traits. In the present study, we found 11
loci hosting variants that have previously been linked to clinical phenotypes. This includes
associations with the estimated glomerular filtration rate (eGFR) and chronic kidney disease
(CKD). Thus, the associated metabolites might, on the one hand, serve as intermediate traits
for clinical endpoints. On the other hand, the associations might provide new insights regard-
ing the involvement of specific metabolic pathways in pathomechanisms and the mediation of
genetic risk loci through metabolic changes. For all 22 GIMs, we provide information on both
the match of gene and metabolite function and the link to clinical traits in Table 3. In the fol-
lowing, we exemplify the value of our results for the characterization of gene functions in the
light of clinical phenotypes.
As a first example, we identified significant associations of variants upstream of ETNPPL
with ethanolamine. Interestingly, at the time when we received the first results from our associ-
ation studies this gene was named AGXT2L1 and was assumed to encode an alanine-glyoxy-
late-aminotransferase. Based on this gene annotation, there was no obvious relation to the
associated metabolite ethanolamine. In such cases, only dedicated experiments (similar to the
one for the carnitine/SLC16A9 association mentioned above [6]) could validate the connection
of ethanolamine to the gene product. Meanwhile, Veiga-da-Cunha et al. experimentally inves-
tigated the locus in an independent study and found that AGXT2L1 actually encodes an
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ethanolaminephosphate-phospholyase [59]. As a consequence, AGXT2L1 now carries the gene
symbol ETNPPL. As ethanolamine is a direct precursor of ethanolaminephosphate via ethanol-
amine kinase (EC 2.7.1.28), our finding indeed matches the actual gene function. Besides the
functional characterization of this locus, Veiga-da-Cunha et al. suggest that the ETNPPL-medi-
ated degradation of ethanolaminephosphate balances the concentration of that metabolite in
the central nervous system. They concluded that an altered ethanolaminephosphate homeosta-
sis might contribute to mental disorders such as schizophrenia [59]. In line with this hypothe-
sis, the ETNPPL expression rate in brain was previously found to be associated with
schizophrenia [60]. ETNPPL is primarily expressed in brain and liver and the encoded protein
is, amongst other tissues, highly localized in the cerebral cortex and the kidney (S4 Table and
The Human Protein Atlas [52], http://www.proteinatlas.org/ENSG00000164089/tissue). Our
results suggest that an excess of ethanolamine in urine could indicate alterations in ethanolami-
nephosphate homeostasis linked to a genetically reduced enzymatic activity of ETNPPL.
As a second example, we identified significant associations of genetic variants with 2-hydro-
xyisobutyrate (2-HIBA) in a locus comprising 9 different genes. According to our evidence-
based locus to gene assignment, 4-hydroxyphenylpyruvate dioxygenase (HPD) is the most prob-
able effector gene candidate. The association between 2-HIBA and this locus represents a well
replicated finding: it was already identified in our previous NMR-based mGWAS in urine [10]
and it has meanwhile also been discovered in an MS-based GWAS with blood metabolites [21].
Nonetheless, to the best of our knowledge, there is no obvious, known biological link between
2-HIBA and theHPD gene or any of the remaining 8 genes covered by this locus. In the litera-
ture, 2-HIBA is often referred to as a secondary metabolite that can be found in urine of
humans and rats exposed to the volatile gasoline additives methyl-tert-butylether and ethyl-
tert-butylether [61–63]. However, 2-HIBA has been identified by both MS- and NMR-based
methods in almost all serum and urine samples of large human cohorts (e.g. ARIC [25],
CoLaus [12], KORA [6, 21], SHIP [10], TasteSensomics [12], and TwinsUK [6, 21]) in rela-
tively high concentrations (~ 40 μM in urine in this study), which suggests sources beyond gas-
oline for this metabolite (e.g. microbiota [64] or medication [65]). Interestingly, Dai et al.
recently showed that 2-HIBA is an intermediate for the newly discovered but common
2-hydroxyisobutyrylation of lysine residues of histones [66], thus indicating an endogenous
role of 2-HIBA. In this context, it is interesting to note that SETD1B is one of the genes within
the identified locus on chromosome 12. SETD1B is a component of the methyltransferase com-
plex that specifically methylates the lysine-4 residue of histone H3 [67]. This residue is amongst
the 63 sites for 2-hydroxyisobutyrylation presented by Dai et al. [66]. Thus, one could speculate
that in addition to its activity as a histone methylase, SETD1Bmay also be involved in the
newly discovered process of histone hydroxyisobutyrylation, a hypothesis that may now be
tested by dedicated experiments.
As a third example, we discuss the association of variants in XYLB with increased urinary
glycolate levels. One of these variants, rs17118, causes an amino acid exchange in the XYLB
gene product. XYLB encodes the enzyme xylulokinase [33], which catalyzes the phosphoryla-
tion of D-xylulose to D-xylulose-5-phosphate. In humans, the vast majority of D-xylulose is
metabolized via xylulokinase [33, 68, 69]. However, there is an alternative metabolic pathway
in which D-xylulose is metabolized by phosphofructokinase (PFK) (S3 Fig) [70]. Therein, one
of the downstream products is glycolate. Thus, the genetic variants in XYLBmight reduce the
enzymatic activity of xylulokinase and thereby cause a shift towards the alternative pathway.
Interestingly, the minor allele of rs17118 has been implicated in increased susceptibility for
ischemic stroke [32]. Furthermore, Jung et al. found a significant association between elevated
glycolate levels in plasma and cerebral infarction [34]. In the alternative pathway, glycolate is a
precursor of oxalate, whose toxic effect has been demonstrated repeatedly [33, 71]. Very
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recently, Rao et al. postulated that circulating oxalate precipitate might be a potential mecha-
nism for stroke [72]. In this context, the association between the SNP rs17118 and glycolate
(identified in our study) suggests that the carriers of this variants have a higher risk of stroke
(identified in [32]) possibly via increased levels of glycolate or oxalate through favoring the
alternative D-xylulose degradation. Unfortunately, oxalate or any other metabolite in the two
D-xylulose degradation pathways are not detected in our metabolomics analysis to further sup-
port our hypothesis.
Extending blood GIMs to urine
In total, 26 genetic loci that associate with urinary metabolic traits are known to date (22 iden-
tified or confirmed in this study plus 4 identified in previous studies [5, 11, 12], Fig 3). Of the
26 loci, only 8 loci lack corresponding SNP-metabolite associations in blood, and, based on
current mGWAS, represent urine specific hits. All of these 8 loci were first reported in the pres-
ent study. In case of the 14 loci with overlapping associations between blood and urine in our
study (Table 3), 6 target the same metabolite in both media (CPS1, AGXT2, DMGDH,
SLC6A13,HPD, SLC5A11). Interestingly, in all but one case (SLC5A11) the genetic effect has
the same direction in both fluids, thus indicating that urine can be regarded as “diluted plasma”
to some extent. For 5 of the 14 loci, we considered the associated metabolic traits in blood and
urine to be biochemically related. Here, the metabolites are either products of the enzyme
coded by the candidate gene (NAT8: N-acetylated compounds), or they are linked through an
enzymatic reaction other than the reaction catalyzed by the candidate gene’s product (NAT2:
1,3-dimethylurate and 1-methylurate [73]; PYROXD2: trimethylamine and dimethylamine
[EC 1.5.8.2]; SLC7A9: lysine and homocitrulline [EC 2.1.3.8]), or they belong to the same
metabolite class (TKT: gluconate and erythronate are aldonates). The observed associations of
related but different metabolites in blood and urine may be indicative either for biochemical
conversions before excretion, or simply be a result of differences in the composition of the
metabolite panels covered by the various mGWAS. In case of the remaining 3 loci, we find no
direct biochemical or metabolic relationship between the metabolites in both media, since
AGXT associates with an unknown compound in blood, PNMT associates with amino acids in
urine and HDL cholesterol in blood, and SLC6A20 targets loosely related amino acid
derivatives.
As an example for parallel effects in blood and urine, we identified an association between
variants in the Carbamoyl-Phosphate Synthetase 1 (CPS1) gene and elevated urinary glycine
levels. The strongest associated SNP rs715 was also identified in previous mGWAS with higher
glycine concentrations in blood [14, 21, 24]. This variant has been highlighted previously as a
putative regulator of CPS1 expression [74–76]. Furthermore, the second strongest glycine-asso-
ciated SNP rs1047891 causes a non-synonymous mutation (Thr>Asn) in the C-terminal
domain of the CPS1 polypeptide, which hosts the binding site for the allosteric activator N-
acteyl-L-glutamate (NAG) [77]. Both SNPs are therefore potentially causative variants in this
metabolic association. CPS1 is highly expressed in liver (S4 Table) and controls the first step in
the urea cycle: ammonia is catalyzed to carbamoyl-phosphate, which in turn is the entry sub-
strate of the urea cycle. CPS1 deficiency can lead to high ammonia levels in the body (Hyper-
ammonemia, OMIM #237300) (S4 Fig). The association of the CPS1 variants with glycine can
be explained by the conversion of excess ammonia to glycine via the glycine cleavage system
[78, 79] and is thus biologically meaningful. The association between common variants in
CPS1 and glycine might therefore be driven by mild forms of genetically induced Hyperammo-
nemia. In this study, we could establish a link between genetic factors and a potential urinary
marker for this condition.
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SLC5A11 is the only locus where we observe an association with exactly the same metabolite
in blood and urine but with reversed effects: whilemyo-inositol concentrations in urine
increase per effect allele copy of the lead SNP, they decrease in serum (Table 3) [21]. The Solute
Carrier Family 5 (Sodium/Inositol Cotransporter),Member 11 (SLC5A11) is a co-transporter of
myo-inositol with sodium [80]. SLC5A11 was postulated to play a role in the regulation of
serummyo-inositol concentrations [81], which was recently confirmed by an mGWAS in
blood [21]. On the one hand, the influence of SLC5A11 onmyo-inositol concentrations has
been linked to apical transport and absorption in intestine [82]. On the other hand, SLC5A11
may be implicated in the re-absorption ofmyo-inositol in the proximal tubule of the kidney
[83]. The opposite direction of the genetic influence in blood and urine as observed in our
study suggests that SLC5A11 is actively involved in the re-absorption ofmyo-inositol. This
assumption is further supported by the strong increase of the association strength when testing
the ratio between urinary and serummyo-inositol. This could indicate that the reduced levels
in blood are indeed caused by a reduced re-absorption rate in subjects that are homozygous
regarding the effect allele.
As these examples demonstrate, mGWAS in urine extend our understanding of genetically
influenced biochemical processes and can facilitate the knowledge transfer from blood to urine
and vice versa. Currently, this transfer is limited by the comparatively low number of GIMs in
urine (26) versus blood (>150). Further increasing the sample sizes of mGWAS in urine and
the application of more sensitive MS-based metabolomics platforms as already used for blood
mGWAS could compensate this bias.
Methods
Study samples
For this study, we used data from SHIP (Study of Health in Pomerania) and, for replication,
from the KORA (Kooperative Gesundheitsforschung in der Region Augsburg) study. Both
studies have been described extensively in the study design papers [84–86] and in our previous
publications [4, 6, 10, 21].
SHIP is a longitudinal population study conducted in West-Pomerania, located in the
northeastern part of Germany. 4,308 inhabitants in that region participated in the first phase
“SHIP-0”. For the GWAS presented here, metabolically characterized urine samples and geno-
type data were jointly available for 3,861 study participants (1,960 female and 1,901 male, aged
20 to 81 years). KORA is a population study conducted in the municipal region of Augsburg in
southern Germany. The KORA F4 cohort comprises 3,080 subjects. For the study presented
here, both genotype and urine samples from 1,691 participants (865 female and 826 male, age
32 to 77) were available. In both studies, all participants have given written informed consent
and the local ethics committees (SHIP: ethics committee of the University of Greifswald;
KORA: ethics committee of the Bavarian Chamber of Physicians, Munich) have approved the
studies.
Metabolomics data acquisition and processing
NMRmeasurements. In SHIP-0, non-fasting, spontaneous urine samples were collected
from the study participants. In contrast, KORA F4 study participants were overnight-fasting
prior to urine sample collection. All urine samples were stored at -80°C until the analysis. In
preparation for the recording of NMR spectra, 75μl of phosphate buffer were added to 675μl of
urine to set the pH to 7.0 (+/- 0.35). The deuterated buffer contained 0.5 mM sodium tri-
methylsilylphosphate (TSP) to provide a reference substance for the annotation of the NMR
spectra. One-dimensional 1H NMR spectra were recorded at the University of Greifswald,
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Germany using a Bruker DRX-400 spectrometer (Bruker BioSpin GmbH, Rheinstetten, Ger-
many). Spectra were acquired at 300K and a frequency of 400.13 MHz using a standard one-
dimensional NOESY-PRESAT pulse sequence with water peak suppression, as previously
described in [10].
Targeted analysis. The Fourier-transformed and baseline-corrected NMR spectra were
manually annotated by spectral pattern matching using the ChenomxWorksuite 7.0 by Che-
nomx, Inc. (Edmonton, Canada) to deduce absolute urinary metabolite concentrations. The
panel of targeted metabolites comprises 60 compounds (including creatinine, which was used
for normalization). In the discovery mGWAS, we used both metabolite concentrations (59)
and pairwise ratios thereof (59 × 58/2 = 1,711) from the SHIP-0 data as phenotypic traits. Prior
to analysis, individual metabolite concentrations were normalized to the annotated creatinine
levels, and both concentrations and ratios were log10 transformed. Individual data points more
than three times the standard deviation away from the mean were removed to avoid spurious
associations. Finally, we considered only metabolic traits with at least 300 valid data points for
the GWAS. In total, the final SHIP-0 data set comprises 1,518 targeted metabolic traits (55
metabolites and 1,463 ratios) that were tested for genetic associations.
Likewise, we processed the NMR spectra originating from the KORA F4 data set that was
used for replication. Due to the smaller data set size, we lowered the burden for non-missing
values to 100. The replication data set contains 53 metabolites and 1,359 pairwise ratios. It cov-
ers all metabolic traits that significantly associated in the discovery GWAS.
Non-targeted analysis. The same Fourier-transformed and baseline-corrected NMR spec-
tra that were used for the targeted analysis were binned at a segment width of 0.0005 ppm. All
signal intensities were normalized to the TSP reference peak. We used the FOCUS software
(http://www.urr.cat/FOCUS) [13] for the subsequent processing of the NMR spectra. We
excluded the spectral regions between δ = 4.6 and 5.0 ppm (water peak) and the regions
below δ = 0.0 and above δ = 10.0 ppm, which do not contain any signals relevant for a meta-
bolomics analysis. We performed the spectral alignment and feature extraction using the
default parameters of FOCUS, resulting in a total of 166 NMR peaks in SHIP-0 and 217
peaks in KORA F4. As for the targeted data set, we computed pairwise ratios of the NMR
peaks (SHIP-0: 13,695; KORA F4: 23,436). To compensate for dilution effects, we addition-
ally normalized the signal intensities of individual NMR peaks to the annotated creatinine
concentrations prior to analysis. All non-targeted traits (i.e., NMR peaks and peak ratios)
were log10 transformed. In comparison to the targeted data set, we chose a less stringent
removal of extreme values. Here, individual data points more than four standard deviations
away from the mean were removed.
Genotype data
Both SHIP and KORA samples were genotyped using Affymetrix Human SNP Array 6.0 gene
chips. SNPs were called using the Birdseed2 algorithm. In both data sets, the total genotyping
rate was above 99%. 909,508 SNPs were genotyped in the SHIP-0 cohort, and 906,716 SNPs in
the KORA F4 cohort. We excluded SNPs that violated the Hardy-Weinberg equilibrium
(PHWE< 1.0×10
−6, 8,623 in SHIP and 32,033 in KORA), or had a genotyping rate below 95%
(57,160 in SHIP and 84,351 in KORA), or displayed minor allele frequencies (MAF) below 5%
(227,967 in SHIP and 224,723 in KORA). After the exclusion, 620,456 autosomal SNPs
remained in the SHIP-0 data set and 593,830 autosomal SNPs in the KORA F4 data set. Both
SHIP and KORA genotypes were imputed in a two-stage process (pre-phasing followed by
imputation). According to data from the 1000 genomes project (phase 1, March 2012 release
[50]), we used SHAPEIT (v1.416) [87] for phasing in KORA F4 and IMPUTE (v2.2.2) [88] for
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imputation in KORA F4 and both phasing and imputation in SHIP-0. For the association anal-
yses, we considered only imputed variants with a MAF 5%, PHWE 1.0×10−6, and an impu-
tation quality score (IMPUTE info-score) 0.8.
Statistical analysis
Genome-wide association study. In both the SHIP-0 and KORA F4 cohorts, we used
PLINK (v1.07) [89] to compute age- and sex corrected linear regression models under the
assumption of an additive genetic model. For the discovery study based on the SHIP-0 data set,
we carried out association tests for each genotyped autosomal SNP (filtered for the criteria
described above) and all 15,379 targeted and non-targeted metabolic traits. In addition, we
tested all imputed, quality-filtered SNPs within a physical distance of 1 Mb to each genotyped
SNP that displayed an association signal of P< 5×10−8. This two-stage approach of testing
imputed variants in selected candidate regions results in a drastically lowered computational
burden when compared to association studies with imputed variants over the whole genomic
range (0.9M vs. 15.9M tested SNPs). We considered associations to be genome-wide significant
if the resulting P value was below the Bonferroni-adjusted significance threshold of 5×10−8/
15,379 = 3.25×10−12. In case of associations with ratios, we imposed an additional significance
criterion on the P-gain as suggested by Petersen et al. [53]. P-gain describes the observed
increase in strength of association when compared to the association with the individual meta-
bolic traits from which the ratio was computed (min(P(M1)/P(M1/M2), P(M2)/P(M1/M2))). A
conservative Bonferroni-type lower limit on the P-gain at a significance level of 5% is given by
ten times the number of tested ratio pairs. Thus, associations with ratios were considered to be
significant if the P-gain exceeded 15,180 in case of targeted metabolic ratios and 138,610 in
case of non-targeted ratios. The analysis of the PLINK output files was performed using in-
house R (v3.0.2) code (available at http://www.gwas.eu).
Replication of association results. To replicate the significant associations discovered in
the SHIP-0 data set, we used data from the independent KORA F4 cohort. For each genetic
locus, we attempted to replicate the association of the SNP/metabolic trait pair that displayed
the lowest P-value (S1 and S2 Tables). If an association did not replicate, we checked whether
the tested SNP was significantly associated with other metabolic traits in SHIP-0. In that case,
we tried to replicate these associations, beginning with the one that displayed the strongest
association signal. To replicate associations with non-targeted traits, we selected the NMR fea-
ture with the minimum difference in chemical shift. In total, we attempted the replication of 38
SNP/metabolic trait associations. Thus, we considered associations with P< 0.05/
38 = 1.32×10−3 to be successfully replicated in the KORA F4 cohort.
Genetic variant annotation and evidence-based locus to gene mapping
Annotation data for genetic variants as well as linkage disequilibrium (LD) data from the 1000
genomes project (phase 1 version 3, EUR panel [50]) were retrieved from SNiPA v1 (http://
www.snipa.org) [51]. Full lists of association signals from the serum-based mGWAS [21] were
obtained from the Metabolomics GWAS server (http://www.gwas.eu).
All genotyped and imputed SNPs that displayed genome-wide significant association signals
(according to the aforementioned P-value and P-gain criteria) were assigned to distinct genetic
regions (loci), based on a physical distance threshold of 1 Mb. Each of the resulting 23 genome-
wide significant loci was then projected to candidate genes using an evidence-based procedure.
To this end, we used the “block annotation” feature of SNiPA on the LD-extended (r2 0.8)
list of associated variants at each locus. This feature provides a condensed view of genes that
are linked to any of the significantly associated variants or their LD-proxies via genomic
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proximity, eQTL association, or regulatory elements. Additionally, the block annotation high-
lights missense and pathogenic variants. Based on these data, we defined the following criteria
to identify candidate genes: 1) Genomic proximity: genes that harbor or are in close proximity
(<5kb) to any of the variants in the list. 2) eQTL association: genes where altered expression
levels have been discovered to associate with any of the variants in the list. 3) Regulatory ele-
ments: potentially regulated genes that are associated with a promoter/enhancer/repressor ele-
ment containing a variant of the list. Further evidence for potential involvement of a gene was
assumed if 4) the variant list contains a missense variant for a protein product of this gene and
5) if an intragenic variant in the list is annotated as pathogenic in one of the phenotype data-
bases contained in SNiPA. For each gene, we counted how many of the aforementioned criteria
are met. Thus, the maximum evidence count for a candidate gene is five. If evidence-based
gene selection was ambiguous, the gene with the most plausible biological function was chosen
(S3 Table).
Metabomatching of non-targeted NMR traits
Metabomatching [12] is an automated annotation method that identifies metabolites likely to
underlie an observed genetic association between a SNP and one or more non-targeted meta-
bolic traits (www.unil.ch/cbg). It does so by comparing the association signal between a SNP
and all non-targeted traits (pseudo-spectrum or association spectrum) to the 1H-NMR spectra
of metabolites in a reference set, and assigning a score to each pseudo-spectrum to NMR spec-
trum match. The metabolites most likely to underlie the genetic association are the ones with
the highest scores. We applied metabomatching to each SNP showing a significant association
with an NMR feature or feature-ratio, using the 180 metabolites listed in the urine metabolome
database [54] with an experimental NMR spectrum as reference set. The urine metabolome
database is the subset of metabolites in the Human Metabolome Database (HMDB) [90] pres-
ent in urine. Where indicated, 2-compound or effect direction-specific metabomatching was
applied. Final candidates were manually identified, usually among the few top-ranked matches.
Most likely candidates are used in the text; potential alternatives are listed, along with the meta-
bomatching details, in S1 Fig.
Supporting Information
S1 Fig. Metabomatching on SNPs associated with non-targeted metabolic traits. The subfi-
gures (a)-(s) show the most likely candidate metabolite as suggested by metabomatching for
each locus in Table 2 (except HIBCH, for which no match was found). Top panels contain the
pseudo-spectrum of the SNP with the strongest association within its locus, bottom panels
show the NMR spectrum of the most likely candidate metabolite(s). For pseudo-spectra, only
peaks with-log(P)> 1.3 (P< 0.05) are displayed, and peak color indicates effect direction, with
blue for β> 0 and orange for β< 0. The most likely candidate metabolite is not necessarily the
metabolite of top rank: instead, it is manually selected among top-ranked metabolites. For
some loci, the pseudo-spectrum indicates the involvement of more than one compound. For
CPS1 (b) andHPD (o), 2-compound metabomatching, which ranks compound pairs rather
than individual compounds, produces viable candidates. For SLC6A19 (g), NAT2 (k), and
PNMT (r), the pseudo-spectra allow too many viable compound pairs even for 2-compound
metabomatching, so these matches were manually selected.
(PDF)
S2 Fig. Regional association plots, box plots, and quantile-quantile plots for the loci with
genome-wide significant associations. Top: The regional association plot displays SNPs in a
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locus and the strength of association to the top-associated metabolic trait (Tables 1 and 2). The
plot window (500 kb) is centered on the SNP that displays the strongest association signal and,
in case of ratios, meets the P-gain criterion (“lead SNP”, indicated in blue). The variants are
colored according to the degree of linkage disequilibrium (LD) to the lead SNP. The plot sym-
bols and border colors indicate functional annotations (e.g. effects on transcripts) as well as
results from other association studies. Plots were created with the SNiPA web service (available
at www.snipa.org) using data from the 1000 genomes project (phase 1 version 3, European
super-population) and Ensembl 75. Bottom left: Top associated metabolic trait in SHIP-0
grouped by genotype of the lead SNP (in order major allele homozygotes, heterozygotes, and
minor allele homozygotes). Bottom right: Quantile-quantile plots displaying the observed vs.
the expected distribution of P-values for associations to the top-associated metabolic trait.
(PDF)
S3 Fig. Polymorphisms in XYLBmight induce a switch to an alternative xylulose pathway
via phosphofructokinase (PFK). The mGWAS identified significant associations of SNP
rs3132440 (intronic region of XYLB) and rs17118 (non-synonymous variant in XYLB) with
glycolate. The urinary concentration increases per copy of the effect allele (indicated by the yel-
low arrow). Glycolate is a downstream product of the PFK-mediated D-xylulose pathway.
Thus, the associated variants could decrease the enzymatic activity of XYLB’s gene product
(xylulokinase; XK), which would lead to an increased D-xylulose metabolism via PFK.
Figure adapted from [70, 91].
(PDF)
S4 Fig. Potential relationship between CPS1 deficiency and elevated glycine levels. A defi-
ciency of Carbamoyl-Phosphate Synthetase 1 (CPS1) can lead to high ammonia levels in blood
(top). We detected significant associations of variants in CPS1 and elevated urinary glycine lev-
els (indicated by the yellow arrow). We hypothesize that the excess ammonia is converted to
glycine via the Glycine Cleavage System (bottom).
(PDF)
S1 Table. Replication results for the 15 lead SNPs and their associations to targeted meta-
bolic traits in the KORA F4 cohort. In case of association to ratios, the metabolite that shows
the stronger association signal is listed in the numerator. Tests: number of conducted association
tests on the SNP. The significance level was adjusted for 38 tests (P< 0.05/38 = 1.32×10−3),
which is the sum of replication attempts using targeted traits and non-targeted traits (S2 Table).
In the targeted data set, the strongest identified association between rs7247977 (SLC7A9) and the
lysine/valine ratio could not be replicated. Instead, the second-strongest, still significant associa-
tion of this SNP with the concentrations of valine was successfully replicated.
(DOCX)
S2 Table. Replication results for the 20 lead SNPs and their associations to non-targeted
metabolic traits in the KORA F4 cohort. Non-targeted traits are reported as chemical shifts (i.e.,
the position in the NMR spectrum). To replicate the non-targeted association results, we selected
the NMR peaks or ratios thereof that were closest to the NMR features used in the SHIP-0 data set.
For five loci (ETNPPL, SLC6A19,DMGDH, ABO, and PNMT), we were unable to replicate the top
associations in the KORA F4 data set. These associations are marked with an asterisk ().
(DOCX)
S3 Table. Evidence-based locus-to-gene assignment.
(XLSX)
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S4 Table. Gene expression rates from the Illumina Body Map Project 2.0. Expression rate
(given as reads per kilobase of transcript per million mapped reads; RPKM) for the most likely
effector gene per locus as determined in 16 different tissues.
(DOCX)
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